International Journal of Engineering and Applied Computer Science
Volume: 04, Issue: 01, February 2022

Mesenchymal Stem Cells and Their Use in Inflammatory Bowel Illness

Nour Elamal A. Elashhab
Department of Biology
Faculty of Science, Alasmarya University
Zliten, Libya

Karima R. Zarug Edawib
Department of Biology
Faculty of Science, Alasmarya University
Zliten, Libya

***Abstract*—New pharmacological, surgical, and endoscopic therapies have recently been developed to treat IBD. Among them, stem cell treatment is still in its early stages, despite the fact that multiple studies show that stem cell therapy's immunomodulatory function may decrease inflammation and tissue harm in IBD patients. Intralesional transplantation of autologous or allogeneic MSCs can be deemed a safe and successful therapeutic method for mending perianal fistulas in CD patients, according to this research, which analyses randomized clinical trials and their potential relevance. We did a thorough search of the literature to find research that looked into the function of stem cell treatment in IBD. Since multiple clinical trials have documented exacerbations of IBD following intravenous infusion of MSCs, this literature raises safety concerns about the systemic administration of MSCs.**

Keywords - Biology, Cells; Mesenchymal Stem; Bowel Illness.

I. INTRODUCTION

Inflammatory bowel disorders (IBDs), which include Crohn's disease (CD) and ulcerative colitis (UC), are chronic inflammatory illnesses of the gastrointestinal tract that have an exacerbation and remission phases. [1]. Although the actual cause of IBDs is unknown, various factors, including genetic, microbial, and environmental factors, as well as an abnormal immune response to the gut, have been implicated in the disease's development and progression. The family history of a person is a substantial and independent risk factor for getting IBD. [2]. IBD sufferers' families are unquestionably at a higher risk of developing the disease. For example, 13 percent of monozygotic twins have concordance with IBD, and the frequency of UC is many times greater among Ashkenazi Jews than in other ethnic groups, indicating that genetic background has a role in the development of IBD. In newly industrialized countries, there has been a sharp increase in IBD hospitalizations, suggesting that environmental variables are linked to the development and progression of IBD. Cigarette smoking has been shown in several epidemiological studies to increase the likelihood of acquiring CD while lowering the risk of hepatitis C infection [3-5]. Changes in the gut microbiota induced by repeated gastrointestinal infections have been linked to prolonged activation of the intestinal immune response, as well as a twofold risk of developing IBD in genetically vulnerable individuals.

When protected cells such as dendritic cells, macrophages, and T lymphocytes interact with bacterial lipoproteins and lipopolysaccharide, they can activate pro-inflammatory macrophages (M1) and DCs invading the gut, causing IBD (LPS). Actuated M1 macrophages subsequently make a slew of inciting cytokines, allowing a significant inflow of flowing leukocytes, neutrophils, and DC) into the afflicted gut, encouraging chronic enteritis [6].

Ingested bacterial antigens are converted to T cells by T cells, preparing them for a negative T-cell safe response. The gut release pro-inflammatory cytokines (IFN-, TNF-, and IL-17), which activate macrophages and neutrophils in an IFN-dependent and IL-17-dependent manner, resulting in a 'positive inflammatory loop.' Activated type (M2) macrophages, in contrast to inflammatory cells, operate as immune-regulatory cells in the gut, lowering detrimental immune responses and promoting gut remodeling and mucosal repair in an IL-10, TGF, and PGE2-dependent way. Provocative T cells, TGF DCs, and IL-10 are all suppressed by regulatory T lymphocytes (Tregs), which help to form the immunological gut environment. [7].

The colon is the focus of pathological alterations in UC patients, although CD be able to change the whole intestinal system. They can both cause stomach discomfort, fever, cramps, diarrhea, blood in the stool, exhaustion, and weight loss. These symptoms have a significant impact on a patient's capacity to live a normal life and can be deadly in some cases [8].

The 5-ASA drugs and antibiotics, together with immunomodulatory pharmaceuticals, are now considered standard treatment for IBD patients. However, because none of the currently known medications can completely erase inflammation in IBD patients' gastrointestinal tracts, this health therapy can just cause a medical reduction. As a result, novel treatment approaches for IBD are badly needed [9].

MSCs (Mesenchymal stem cells) are self-renewing cells that can suppress the immune system and differentiate into a

variety of cell types, including gastrointestinal epithelial cells. MSC-mediated intestinal inflammation reduction and MSC-dependent gut epithelial regeneration were revealed to be responsible for their therapeutic advantages in IBD patients. This chapter on the use of MSCs in the treatment of inflammatory bowel disease (IBD) focuses on present evidence and prospects [10].

II. EMBEDDED MESENCHYMAL STEM CELLS IN INFLAMMATORY BOWEL DISEASE

During the stages of clinical testing of cancer stem cells for the treatment of disease, several problems arose that prompted researchers to develop sound strategies. The immune-mediated or anti-inflammatory properties of CSCs can produce quite opposite phenomena in inflamed environments. The major challenge in the treatment of IBD and clinical CAC has been the low efficacy of MSCs due to low survival and immunosuppressive capacity when translocated to the intestinal mucosa. Therefore, many technical departments have used MSCs to treat IBD and CAC to solve these difficulties. These treatments can be mainly divided into two types: those that enhance immunomodulatory function and those that improve survival in vitro and in vivo.

A. Improve cancer stem cells

To improve cancer stem cells' immune modifying activity in inflammatory bowel disease. Several methods will be used to improve the immune-modulating function of mesenchymal stem cells in IBD, including genetic modification of CSCs achieved through overexpression induced by plasmid and adenovirus transfection; it is also possible to use MSCs in combination with microRNA (modulators of cell function), a type of non-coding RNA, to provide relatively safe treatment. Increased CXCR4 expression is thought to hasten the diversion of BMMSCs to intestinal damage sites. While genetic editing has a number of benefits, it also has the potential to cause cancer. Immunosuppressive cytokines are secreted by MSCs pre-coupled with TLR3, which limit active T-cell proliferation, worsening the gut inflammatory process. Because the immature technology has kicked off a cascade of hazardous responses in practice, strategies to boost immune function in CSCs have not proven any benefit in preclinical studies for treating IBD [11].

B. CSCs associated

CSCs associated with inflammatory bowel illness should have better in vitro and intracellular survival. MSCs can be more easily preserved and transferred in a spherical shape to play a very effective role in the treatment of experimental enteritis in vivo by using melatonin for senescence and additional colony formation in vitro; MSCs can also be more easily preserved and transferred in a spherical shape to play a very effective role in the treatment of experimental enteritis in vivo by using melatonin for senescence and additional colon.

III. PREACTIVATION OF MSCS AND PREPARATION OF MSC-CONDITIONED MEDIUM

Blood was extracted from the carotid artery and collected in a clot-stimulating tube in a study on animals with colitis. The serum was separated from the blood by centrifuging it at 3000 rpm for 10 minutes, and the supernatant was filtered twice through 0.45 and 0.22 m membranes before being recovered from the colitis mice's serum.

The fat-containing MSCs were stained in full culture media at a concentration of 1 10 cells/mL in 75 cm 2 flasks and incubated at 37°C and 5% CO. The culture media and nonadherent cells were removed when the cells achieved 80% confluence. MSCs were treated with full medium with 10% rat colitis serum for 24 hours to create activated MSC-conditioned media. Colitis serum-treated (CM-AcMSC) or untreated (CMMSC) conditioned media were collected, centrifuged for 10 minutes at 2000 rpm to eliminate impurities, and filtered twice through 0.45 and 0.22 m membranes, respectively. The conditioned medium was then given to colitis mice by intravenous injection [12].

IV. MSC-BASED BENEFICIAL EFFECTS IN THE TREATMENT OF IBDS: MOLECULAR MECHANISMS

Expected in the direction of their immunoregulatory features, cancer stem cells are emerging as a viable cell treatment for IBD. All immune cells, including those implicated in the aggravation and remission of IBD, have been demonstrated to be influenced by cancer stem cells in terms of proliferation, activation, and effector function. The protected system is influenced by MSCs in a juxtacrine or paracrine manner. Because MSCs cannot produce cost molecules. The CSCs diminish the existence of effecter T cells in the swollen GI zone, decreasing inflammation caused by Th1 and Th17 [13, 14].

MSCs may reduce ongoing T cell-dependent inflammation by producing immunosuppressive chemicals, and nitric oxide (NO), as well as via paracrine and juxtacrine pathways. MSCs restrict the clonal proliferation of activated T cells in a PGE2-dependent way by downregulating IL-2 receptor expression. TGF- is also a powerful inhibitor of the IL-2 signaling pathway, and so contributes to activated T cell G1 cell cycle arrest produced by MSCs. MSC-derived NO and IDO, like NO and IDO, limits T cell growth by altering the cell cycle or metabolism.

Furthermore, MSCs regulate the antigen-presenting activity of DCs via PGE2, IL-10, and IL-6, preventing the development of Th1 and Th2. DCs stimulate M1 inflamed macrophages to polarise toward the M2 immunosuppressive phenotype, establishing a potential phenotype. CSCs reduce inflammatory cytokines (TNF-, IL-1, and IL-12) production while enhancing anti-inflammatory cytokines (IL-10 and TGF-), leading to better tissue repair and regeneration. [15]. M2 macrophages and tolerant DCs also increase the production of human immunosuppressive leukocyte antigen (HLA)-G5 in MSCs, which improves their ability to stimulate the generation and expansion of Tregs in an IL-10 and TGF-dependent manner,

contributing to the formation of an anti-inflammatory microenvironment in the intestine [16].

During the remission of IBD, epithelial cell interaction with invading immune cells in the gut is critical for mucosal repair of the injured gut mucosa. In the presence of keratinocyte growth factor (KGF), hepatocyte growth factor (HGF), epidermal growth factor (EGF), and insulin-like growth factor-II, CSCs can transform into intestinal epithelial cells in vitro, making it a viable factor. A source of intestinal epithelial renewal. However, because MSCs can acquire the phenotypic and functional properties of intestinal epithelial cells by fusion with resident intestinal epithelial cells, the exact process of MSC-dependent epithelium regeneration in vivo is uncertain [17].

V. M SCs AS A NOVEL THERAPEUTIC APPROACH FOR THE TREATMENT OF IBD PATIENTS' PERIANAL FISTULAS

According to epidemiological research. These fistulas are frequently treated in a progressive manner, with surgical therapy followed by the administration of immunomodulatory medications as well as biologics These therapeutic techniques did not lead to an increase in the amount of sinus finish in nearly partial of CD affected role, so many medical court-martials remained led toward examining the beneficial possible of intraoral stem cells in treating perianal sinuses for CD affected role. Local administration of cancer stem cells to treat CD fistula may, according to the data, be a unique and viable treatment technique in the near future so that it can be fully utilized for the patient. [18].

Because MSCs produced from IBD patients and healthy persons have similar morphological and functional properties were employed in the majority of clinical studies. Importantly, the source of transplanted MSCs and the treatment dose had a substantial impact on their efficacy. Bone marrow (BM) and adipose tissue (AT) were the most common sources of autologous MSCs.

Low MHC molecule expression on the cell surface, ease of handling and in vitro replication, genetic stability, and multilineage differentiation potential are just a few of the numerous benefits that might make BM-MSCs suited for therapeutic use. shown in (Fig. 1).

Several studies found that locally transplanted BM-MSCs were effective in treating perianal fistulas in CD patients [16, 19-21]. Intrafistular injections of autologous BM-MSCs were well tolerated and efficacious in the repair of 10 CD patients' actively draining, complicated, perianal, and enterocutaneous fistulas. Over the course of a month, all patients got 20,106 autogenous BM-MSC injections with no negative effects. AT-MSCs and BM-MSCs are given systemically to IBD affected role and show complete healing of the rectal mucosa as well as a substantial improvement in the Crohn's disease activity index. Inflammatory cytokine production (IFN-, TNF-, and IL-6) by immune cells may be inhibited, resulting in BM-MSC immunological responses. Immune cells are also stimulated by BM-MSCs to secrete anti-inflammatory chemicals such as TGF, IL-10, and VEGF, which all promote angiogenesis, tissue repair, and regeneration. AT-MSCs also have good immune-regulatory capacities, reducing T-cell production and hence lowering T-cell proliferation. Th17-expressing Th1 and RORT, as well as IL-12 and TNF, release inhibition in protected cells [22].

In 70% of BM-MSC-treated CD patients, the perianal disease activity index (PDAI) and the CDAI were seen. Furthermore, in the inflammatory portions of the wounded colons, a considerably as huge number of guts infiltrating Tregs was seen, leading to the reduction of ongoing inflammation.



Figure 1: AT-MSCs and BM-MSCs have therapeutic promise in the conduct of IBD-affected roles.

Given that obtaining BM-MSCs necessitates the reaping of BM, which is a very offensive technique, alternate bases of MSCs, such as AT, have been vigorously investigated. AT-derived MSCs (AT-MSCs) are more readily retrieved after IBD affected role by suction lipectomy than BM-MSCs and are frequently obtained in bigger numbers. Furthermore, AT-MSCs exhibit significant immunomodulatory capabilities, allowing them to decrease the development of Th1 and Th17 cells in the gut while also promoting the proliferation of immunosuppressive Tregs (Figure 1).

Autologous AT-MSCs, like BM-MSCs, successfully repaired fistulas in CD patients. Six AT-MSC-treated CD patients had fistulas entirely cured after a single intrafistular transplantation of 3-30x106 autologous AT-MSCs, while an extra two-CD patient who received AT-MSCs had partial closure of perianal fistulas. During a 22-month follow-up, CD patients reported any adverse effects from MSC-created treatment. In phase II clinical study, the therapeutic potential of locally administered AT-MSCs was verified, with fistula repair occurring in 17 of 24 CD patients. The quality of life of all CD-affected roles who conventional AT-MSCs has improved significantly [19].

Two recent clinical investigations [23, 24] revealed the favorable benefits of autologous AT-MSC-based therapy of fistulizing CD, which corroborate our findings. AT-MSCs intralesionally healed their perianal fistulas completely without any symptoms of drainage or inflammation.

Despite the fact that the ideal amount of MSC to completely seal the fistula has yet to be discovered, practically all clinical studies have used a consistent schedule of MSC administration to CD fistula patients. All clinical studies have shown that MSC-mediated fistula healing lasts at least a year, the representative that MSCs container regarded as innovative beneficial mediators in cell-based sinus closure [25].

VI. In the Treatment of Inflammatory Bowel Illnesses, Stem Cells Administered Intravenously Have Therapeutic Benefits

In some clinical studies including MSCs for the treatment of severe inflammatory bowel disease, systemic delivery of BM-MSCs has to be used. In a phase II study, nine patients with moderate to severe CD were trialed to give an intravenous injection of 2,102 or 8106 BM-MSCs/kg body weight. The result is that only one patient treated with BM-MSC achieved complete clinical remission, while five individuals experienced unfavorable side effects after intravenous MSC infusion [26].

When CSCs are transplanted into the gut, large levels of IFN- and TNF polarise into immunosuppressive cells, which limit damaging intestinal immune responses and reduce chronic intestinal inflammation. MSCs develop a pro-inflammatory phenotype and release a significant number of inflammatory mediators if IFN and TNF receptors do not provide adequate intracellular signals (IL-1, IL-6, and IL-8) [27].

The idea that a high amount of IFN- boosts MSC therapeutic potential in vitro and in vivo has been proven. In vitro suppression of secondary blood mononucleate cells and T lymph cells were achieved by pre-treating human BM-MSCs with IFN-. In their peripheral lymphoid organs, rats given along with IFN-primed MSCs got considerably more Tregs and significantly fewer Th1 and Th17 cells than mice treated with IFN-non-ready MSCs [23, 24]. When IFN-priming MSCs, a difficulty arises because this cytokine has a tendency to boost the production of MHC grade 1 and 2 proteins, with cost molecules, on the MSC surface. According to our investigation, if MHC-mismatched patients were given mesenchymal stem cells that had been primed with IFN-, allogeneic immune responses would be substantially stronger than non-IFN-stimulated stem cells, resulting in allogeneic MSC rejection, as seen in Figure 2.



Figure (2): indicates that the IFN-γ undercoat of CSCs meaningfully improves the immunosuppressant capabilities of BM-MSCs.

VII. MSC-Based Therapy for IBDs Faces a slew of Obstacles

Results from previously completed clinical studies revealed a number of obstacles that must be overcome in order to safely and effectively transplant MSCs into IBD patients.

First, future clinical studies should thoroughly examine the relationship between transplanted MSCs and immunosuppressive medications. In IBD patients, the majority of presently utilized immunomodulatory medications suppress the Th1 immune response, resulting in lower stages of IFN- in the wounded stomach. MSCs have a provocative character once they insert the milieu through low levels of IFN-, patients who receive MSCs in conjunction with medications that inhibit the protected reaction might anticipate a worsening of IBD. Lindsay and associates recently proposed this idea after seeing an elevated prevalence of severe gastrointestinal infections followed by disease aggravation in IBD patients who had cyclophosphamide immediately before stem cell transplantation [28].

After all, because of their multilineage isolation capacity, the MSCs may develop keen on undesirable cell varieties after engraftment, which severely limits their therapeutic application in the treatment of IBD. Moreover, to undesired variation, transplanted MSCs can decrease antitumor immunity and produce neovascularization, which tumor cells may exploit to proliferate and disseminate unhindered in tissues far from the MSC transplantation site

VIII. Conclusion

Cancer stem cells are emerging therapeutic agents in cell-based therapy for inflammatory bowel diseases due to their immunomodulatory and regenerative properties. Intralesional transplantation of autologous CSCs may be considered as a safe and effective treatment method for repairing perianal fistulas in CD patients, according to a large number of randomized clinical studies. Safety concerns have been raised regarding the systemic administration of MSCs. However, since multiple clinical studies have revealed an aggravation of IBD once a venous combination of MSCs, MSCs systemic can provide a rather safe treatment modality.

Because cancer stem cells can distinguish into unwanted cell categories plus aid tumor growing plus evolution, medical revisions looking into the therapeutic possibility of stem cells would focus on stretched-term monitoring and continuation of affected roles who have received MSC transplants to identify all potential side effects. MSC-based therapy is a promising treatment option. More experimental and clinical research is needed to discover the optimum source of tissue, cell quantity, and administration strategies before MSCs can be utilized as conventional therapy for IBD.

References

[1] L. Berkowitz et al., "Impact of cigarette smoking on the gastrointestinal tract inflammation: opposing effects in Crohn's disease and ulcerative colitis," Frontiers in immunology, vol. 9, p. 74, 2018.

[2] J. Askling et al., "Family history as a risk factor for colorectal cancer in inflammatory bowel disease," Gastroenterology, vol. 120, no. 6, pp. 1356-1362, 2001.

[3] A. Y. Coqueiro, R. Raizel, A. Bonvini, J. Tirapegui, and M. M. Rogero, "Probiotics for inflammatory bowel diseases: a promising adjuvant treatment," International journal of food sciences and nutrition, vol. 70, no. 1, pp. 20-29, 2019.

[4] D. Owczarek, T. Rodacki, R. Domagała-Rodacka, D. Cibor, and T. Mach, "Diet and nutritional factors in inflammatory bowel diseases," World journal of gastroenterology, vol. 22, no. 3, p. 895, 2016.

[5] J. F. Rodemann, E. R. Dubberke, K. A. Reske, D. H. Seo, and C. D. Stone, "Incidence of Clostridium difficile infection in inflammatory bowel disease," Clinical Gastroenterology and Hepatology, vol. 5, no. 3, pp. 339-344, 2007.

[6] C. R. Harrell, V. Djonov, and V. Volarevic, "The cross-talk between mesenchymal stem cells and immune cells in tissue repair and regeneration," International journal of molecular sciences, vol. 22, no. 5, p. 2472, 2021.

[7] H. Chaudhry et al., "Role of cytokines as a double-edged sword in sepsis," In vivo, vol. 27, no. 6, pp. 669-684, 2013.

[8] T. Gramlich and R. E. Petras, "Pathology of inflammatory bowel disease," in Seminars in pediatric surgery, 2007, vol. 16, no. 3: Elsevier, pp. 154-163.

[9] R. Rahimi, S. Nikfar, A. Rezaie, and M. Abdollahi, "Pregnancy outcome in women with inflammatory bowel disease following exposure to 5-aminosalicylic acid drugs: a meta-analysis," Reproductive toxicology, vol. 25, no. 2, pp. 271-275, 2008.

[10] Y. Qi, J. Ma, S. Li, and W. Liu, "Applicability of adipose-derived mesenchymal stem cells in treatment of patients with type 2 diabetes," Stem cell research & therapy, vol. 10, no. 1, pp. 1-13, 2019.

[11] J. Kang et al., "Systematic exposition of mesenchymal stem cell for inflammatory bowel disease and its associated colorectal cancer," BioMed research international, vol. 2018, 2018.

[12] L.-l. Qi, Z.-y. Fan, H.-g. Mao, and J.-b. Wang, "The Therapeutic Efficacy of Adipose Tissue-Derived Mesenchymal Stem Cell Conditioned Medium on Experimental Colitis Was Improved by the Serum From Colitis Rats," (in English), Frontiers in Bioengineering and Biotechnology, Original Research vol. 9, 2021-September-17 2021, doi: 10.3389/fbioe.2021.694908.

[13] C. R. Harrell, C. Fellabaum, N. Jovicic, V. Djonov, N. Arsenijevic, and V. Volarevic, "Molecular mechanisms responsible for therapeutic potential of mesenchymal stem cell-derived secretome," Cells, vol. 8, no. 5, p. 467, 2019.

[14] C. R. Harrell, N. Jovicic, V. Djonov, N. Arsenijevic, and V. Volarevic, "Mesenchymal stem cell-derived exosomes and other extracellular vesicles as new remedies in the therapy of inflammatory diseases," Cells, vol. 8, no. 12, p. 1605, 2019.

[15] M. Gazdic, V. Volarevic, N. Arsenijevic, and M. Stojkovic, "Mesenchymal stem cells: a friend or foe in immune-mediated diseases," Stem Cell Reviews and Reports, vol. 11, no. 2, pp. 280-287, 2015.

[16] A. K. S. Al-Maawali, P. Nguyen, and P. T. Phang, "Modern treatments and stem cell therapies for perianal Crohn's fistulas," Canadian Journal of Gastroenterology and Hepatology, vol. 2016, 2016.

[17] T. Otonkoski, G. M. Beattie, J. S. Rubin, A. D. Lopez, A. Baird, and A. Hayek, "Hepatocyte growth factor/scatter factor has insulinotropic activity in human fetal pancreatic cells," Diabetes, vol. 43, no. 7, pp. 947-953, 1994.

[18] L. Ferrer et al., "Treatment of perianal fistulas with human embryonic stem cell-derived mesenchymal stem cells: a canine model of human fistulizing Crohn's disease," Regenerative medicine, vol. 11, no. 1, pp. 33-43, 2016.

[19] B. S. Markovic et al., "Molecular and cellular mechanisms involved in mesenchymal stem cell-based therapy of inflammatory bowel diseases," Stem Cell Reviews and Reports, vol. 14, no. 2, pp. 153-165, 2018.

[20] C. J. Hawkey and D. W. Hommes, "Is stem cell therapy ready for prime time in treatment of inflammatory bowel diseases?," Gastroenterology, vol. 152, no. 2, pp. 389-397. e2, 2017.

[21] Y. Cao, Z. Ding, C. Han, H. Shi, L. Cui, and R. Lin, "Efficacy of mesenchymal stromal cells for fistula treatment of Crohn's disease: a systematic review and meta-analysis," Digestive Diseases and Sciences, vol. 62, no. 4, pp. 851-860, 2017.

[22] G. Ferrari, B. D. Cook, V. Terushkin, G. Pintucci, and P. Mignatti, "Transforming growth factor-beta 1 (TGF-β1) induces angiogenesis through vascular endothelial growth factor (VEGF)-mediated apoptosis," Journal of cellular physiology, vol. 219, no. 2, pp. 449-458, 2009.

[23] M. Mebarki, C. Abadie, J. Larghero, and A. Cras, "Human umbilical cord-derived mesenchymal stem/stromal cells: a promising candidate for the development of advanced therapy medicinal products," Stem Cell Research & Therapy, vol. 12, no. 1, pp. 1-10, 2021.

[24] C. R. Harrell et al., "Mesenchymal stem cell-based therapy of inflammatory lung diseases: current understanding and future perspectives," Stem cells international, vol. 2019, 2019.

[25] M. Carvello, A. Lightner, T. Yamamoto, P. G. Kotze, and A. Spinelli, "Mesenchymal stem cells for perianal Crohn's disease," Cells, vol. 8, no. 7, p. 764, 2019.

[26] M. B. Murphy, K. Moncivais, and A. I. Caplan, "Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine," Experimental & molecular medicine, vol. 45, no. 11, pp. e54-e54, 2013.

[27] A. Franzke, "The role of G-CSF in adaptive immunity," Cytokine & growth factor reviews, vol. 17, no. 4, pp. 235-244, 2006.

[28] A. K. Berglund, L. A. Fortier, D. F. Antczak, and L. V. Schnabel, "Immunoprivileged no more: measuring the immunogenicity of allogeneic adult mesenchymal stem cells," Stem cell research & therapy, vol. 8, no. 1, pp. 1-7, 2017.